Lacosamide Tablet, Film Coated
FDA Recall NDC 31722-812

FDA Enforcement Report: View Recall Date, Reasons, and Safety Status

Active & Historical Enforcement Reports

The FDA has identified 1 recorded enforcement report(s) associated with Lacosamide (NDC 31722-812). A significant event, classified as Class II, was initiated on Jun 04, 2026 by Camber Pharmaceuticals, Inc.. The reported reason for this action was: "Presence of a Foreign Tablets: Complaint received, possible mix-up of Selexipag 1000 mcg tablet in a bottle of Lacosamide Tablets USP, 100mg."

This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.

Reported Recall Events

June 2026 Class II Recall: Presence of a Foreign Tablets

Recall Number
Class II Ongoing
Reason for Recall
Presence of a Foreign Tablets: Complaint received, possible mix-up of Selexipag 1000 mcg tablet in a bottle of Lacosamide Tablets USP, 100mg.
Initiated
Jun 04, 2026
Reported
Jul 01, 2026
Quantity
31,392 60-count bottles

Recall Profile & Regulatory Data

Event ID
99200
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
Annora Pharma Private Limited
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide in the USA
Product Description
Lacosamide Tablets, USP, C V, 100mg, Rx only, 60-count bottle, By: Annora Pharma Pvt., Ltd, Sangareddy -502313, Telangana, India, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ 08854, NDC 31722-813-60.
Batch or Lot Expiration Information
Lot# Lot: A253999, A254000, Expires: 09/30/2027.
Affected Packages Involved in this Recall
31722-812-60Product
31722-812-18Product
31722-812-05Product
31722-812-32Product
31722-813-60Product
31722-813-18Product
31722-813-05Product
31722-813-32Product
31722-814-60Product
31722-814-18Product
31722-814-05Product
31722-814-32Product
31722-815-60Product
31722-815-18Product
31722-815-05Product
31722-815-32Product

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.